Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH)
Research payments
$15,025,661
Through program year 2025, $15,025,661 in research payments was reported against Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH), across 7,535 payments, paid by Boehringer Ingelheim International GmbH.
- Paid by
- Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $15,025,661 | 7,535 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Guy Neff Sarasota, FL Named on 1,234 payments
- Yaneicy Gonzalez Rojas Coral Gables, FL Named on 1,095 payments
- Charles Smith Canton, OH Named on 1,072 payments
- Humberto Aguilar Shreveport, LA Named on 467 payments
- Bruce Segal Delray Beach, FL Named on 365 payments
- Ronald Surowitz Jupiter, FL Named on 340 payments
- Shekhar Challa Topeka, KS Named on 231 payments
- Robert Jenders Torrance, CA Named on 222 payments
- Rasha Youssef Boynton Beach, FL Named on 217 payments
- Antonio Sanchez Iowa City, IA Named on 187 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.